雷尼替丁

雷尼替丁用途

Ranitidine 是一种有效的,选择性的,具有口服活性的组胺 H2 受体 (histamine H2-receptor) 拮抗剂,IC50 为 3.3 μM,可抑制胃液分泌。Ranitidine 还一种是 CYP2C19 和 CYP2C9 的弱抑制剂。

雷尼替丁名称

[ CAS 号 ]:
66357-35-5

[ 中文名 ]:
雷尼替丁

[ 英文名 ]:
Ratic

[中文别名 ]:

[英文别名 ]:

Taural
Sostril
Terposen
Trigger
U1tidine
Ranitidine
Zantic
MFCD00081180
RANITIDINE USP
EINECS 266-332-5

雷尼替丁生物活性

[ 描述 ]:

[ 相关类别 ]:

信号通路 >> 免疫及炎症 >> 组胺受体

研究领域 >> 内分泌

研究领域 >> 感染

信号通路 >> 代谢酶/蛋白酶 >> 细胞色素P450

研究领域 >> 代谢疾病

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 组胺受体

信号通路 >> 抗感染 >> 细菌

[ 靶点 ]

H2 Receptor:3.3 μM (IC50)

CYP2C19

CYP2C9

[参考文献]

[1]. A W Herling, et al. Inhibition of 14C-aminopyrine accumulation in isolated rabbit gastric glands by the H2-receptor antagonist HOE 760 (TZU-0460). Agents Actions. 1987 Feb;20(1-2):35-9.

[2]. A Leucuta, et al. A pharmacokinetic interaction study between omeprazole and the H2-receptor antagonist ranitidine. Drug Metabol Drug Interact. 2004;20(4):273-81.

[3]. Antonio Francesco Ciccaglione, et al. Pylera® plus ranitidine vs Pylera® plus esomeprazole in first-line treatment of Helicobacter pylori infection: Two pilot studies. Helicobacter. 2019 Oct;24(5):e12606.

雷尼替丁物理化学性质

[ 密度 ]:
1.2±0.1 g/cm3

[ 沸点 ]:
437.1±45.0 °C at 760 mmHg

[ 熔点 ]:
69-70°C

[ 分子式 ]:
C₁₃H₂₂N₄O₃S

[ 分子量 ]:
314.404

[ 闪点 ]:
218.2±28.7 °C

[ 精确质量 ]:
314.141266

[ PSA ]:
111.56000

[ LogP ]:
1.23

[ 外观性状 ]:
白色粉末

[ 蒸汽压 ]:
0.0±1.0 mmHg at 25°C

[ 折射率 ]:
1.559

[ 储存条件 ]:
Desiccate at +4°C

[ 水溶解性 ]:
24.7 mg/mL

雷尼替丁毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: KM6556500

CHEMICAL NAME :: 1,1-Ethenediamine, N-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)th io)ethyl)-N'-methyl- 2-nitro-

CAS REGISTRY NUMBER :: 66357-35-5

LAST UPDATED :: 199703

DATA ITEMS CITED :: 7

MOLECULAR FORMULA :: C13-H22-N4-O3-S

MOLECULAR WEIGHT :: 314.45

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 12 mg/kg/2D-I

TOXIC EFFECTS :: Kidney, Ureter, Bladder - interstitial nephritis Blood - other changes Skin and Appendages - dermatitis, allergic (after topical exposure)

REFERENCE :: AJEMEN American Journal of Emergency Medicine. (WB Saunders, Philadelphia, PA) V.1- 1983- Volume(issue)/page/year: 12,67,1994

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >5 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4613602

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 93 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4613602

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 2018 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4613602

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 884 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: EJMCA5 European Journal of Medicinal Chemistry--Chimie Therapeutique. (Editions Scientifiques Elsevier, 29 rue Buffon, F-75005, Paris, France) V.9- 1974- Volume(issue)/page/year: 25,749,1990

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 80 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4613602

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 280 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4613602

雷尼替丁安全信息

[ 安全声明 (欧洲) ]:
S22-S24/25

[ WGK德国 ]:
2

[ RTECS号 ]:
KM6557000

[ 海关编码 ]:
2932999099

雷尼替丁上下游产品

雷尼替丁上游产品

雷尼替丁下游产品

雷尼替丁制备

5-[(二甲氨基)甲基]-2-呋喃甲醇和半胱氨酸反应，生成2-[[5-[(二甲氨基)甲基-2-呋喃基]甲基]硫代]乙胺。将
N-甲基-1-甲硫基-2-硝基乙烯甲胺溶于水，加热搅拌，滴加上面得到的物质，反应一定时间，加入4-甲基-2-戊酮，经进一步处理得到雷尼替丁。

雷尼替丁海关

[ 海关编码 ]: 2932999099

[ 中文概述 ]:
2932999099. 其他仅含氧杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途

[ Summary ]:
2932999099. other heterocyclic compounds with oxygen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

雷尼替丁相关知识

雷尼替丁的功效与作用。雷尼替丁有什么副作用？

2018-11-07 17:11:46

雷尼替丁属于一组称为组胺-2阻滞剂的药物。它通过减少胃产生的酸量来起作用。用于治疗和预防胃和肠道溃疡。它还治疗胃产生过多酸的情况，例如Zollinger-Ellison综合征。雷尼替丁还治疗胃食管反流病(GERD)和其他酸从胃进入食道的病症，引起胃灼热。雷尼替丁片剂中的活性成分，USP 150...